BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 [PMID: 31011254 DOI: 10.3748/wjg.v25.i14.1684]
URL: https://www.wjgnet.com/1007-9327/full/v25/i14/1684.htm
Number Citing Articles
1
Erik Rösner, Daniel Kaemmerer, Jörg Sänger, Amelie Lupp. Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological dataTranslational Oncology 2022; 25: 101526 doi: 10.1016/j.tranon.2022.101526
2
Jiazhang Xing, Jingci Chen, Tingting You, Zhao Sun, Tao Lu, Yuejuan Cheng, Huanwen Wu, Chunmei Bai. Expression of p53 and Rb reveal subtypes of gastric neuroendocrine carcinoma with distinct prognosisJournal of Neuroendocrinology 2023; 35(4) doi: 10.1111/jne.13257
3
Alexander W. MacFarlane, Ho-Man Yeung, R. Katherine Alpaugh, Essel Dulaimi, Paul F. Engstrom, Arvind Dasari, Kerry S. Campbell, Namrata Vijayvergia. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasmsCancer Immunology, Immunotherapy 2021; 70(7): 1893 doi: 10.1007/s00262-020-02811-5
4
Z Liu, F Mi, M Han, M Tian, L Deng, N Meng, J Luo, R Fu. Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myelomaClinical and Experimental Immunology 2021; 205(1): 53 doi: 10.1111/cei.13594
5
Ilaria Maggio, Lisa Manuzzi, Giuseppe Lamberti, Angela Dalia Ricci, Nastassja Tober, Davide Campana. Landscape and Future Perspectives of Immunotherapy in Neuroendocrine NeoplasiaCancers 2020; 12(4): 832 doi: 10.3390/cancers12040832
6
Satoshi Yamashita, Hiroyuki Abe, Akiko Kunita, Hiroharu Yamashita, Yasuyuki Seto, Tetsuo Ushiku. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinomaHistopathology 2021; 78(3): 381 doi: 10.1111/his.14230
7
He Fei, Ze-Feng Li, Ying-Tai Chen, Dong-Bing Zhao. Hepatoid adenocarcinoma of the stomach with neuroendocrine differentiation: A case report and review of literatureWorld Journal of Clinical Cases 2023; 11(22): 5323 doi: 10.12998/wjcc.v11.i22.5323
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
8
Virginia Corbett, Susanne Arnold, Lowell Anthony, Aman Chauhan. Management of Large Cell Neuroendocrine CarcinomaFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.653162
9
Mengyuan Liu, Elizabeta C. Popa, Brendan M. Finnerty, Thomas J. Fahey, Rasa Zarnegar. Clinicopathological Features of Gastroesophageal Neuroendocrine NeoplasmsCurrent Gastroenterology Reports 2020; 22(10) doi: 10.1007/s11894-020-00788-w
10
He Fei, Ze-Feng Li, Ying-Tai Chen, Dong-Bing Zhao. Hepatoid adenocarcinoma of the stomach with neuroendocrine differentiation: A case report and review of literatureWorld Journal of Clinical Cases 2023; 11(22): 5329-5337 doi: 10.12998/wjcc.v11.i22.5329
11
Zhuo Han, Nan Wang, Qing Qiao, Xianli He, Nan Wang. Association of PD-L1 Expression with Clinicopathologic Characters in Gastric Cancer: A Comprehensive Meta-analysisCurrent Medicinal Chemistry 2024; 31(21): 3198 doi: 10.2174/0109298673263784230922060257
12
Melissa Frizziero, Elaine Kilgour, Kathryn L. Simpson, Dominic G. Rothwell, David A. Moore, Kristopher K. Frese, Melanie Galvin, Angela Lamarca, Richard A. Hubner, Juan W. Valle, Mairéad G. McNamara, Caroline Dive. Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine CarcinomaClinical Cancer Research 2022; 28(10): 1999 doi: 10.1158/1078-0432.CCR-21-3058
13
Guanghui Xu, Yuhao Wang, Hushan Zhang, Xueke She, Jianjun Yang. Immunotherapy and Potential Predictive Biomarkers in the Treatment of Neuroendocrine NeoplasiaFuture Oncology 2021; 17(9): 1069 doi: 10.2217/fon-2020-0703
14
Caroline Lum, Sophia Frentzas. Research and Clinical Applications of Targeting Gastric Neoplasms2021; : 317 doi: 10.1016/B978-0-323-85563-1.00010-1
15
Sevil Karabağ, Meltem Öznur. PD-L1, MMR, and EGFR expression in gastrointestinal neuroendocrine tumorsCukurova Medical Journal 2024; 49(2): 400 doi: 10.17826/cumj.1445549
16
Shuaishuai Xu, Chanqi Ye, Ruyin Chen, Qiong Li, Jian Ruan. The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine NeoplasmsCancers 2022; 14(12): 2911 doi: 10.3390/cancers14122911
17
Eléonore Multone, Stefano La Rosa, Christine Sempoux, Silvia Uccella. PD-L1 expression, tumor-infiltrating lymphocytes, and mismatch repair proteins status in digestive neuroendocrine neoplasms: exploring their potential role as theragnostic and prognostic biomarkersVirchows Archiv 2024; 485(5): 841 doi: 10.1007/s00428-024-03825-5
18
Ze-Feng Li, Hai-Zhen Lu, Ying-Tai Chen, Xiao-Feng Bai, Tong-Bo Wang, He Fei, Dong-Bing Zhao. Mixed large and small cell neuroendocrine carcinoma of the stomach: A case report and review of literatureWorld Journal of Clinical Cases 2022; 10(16): 5502-5509 doi: 10.12998/wjcc.v10.i16.5502
19
Jiazhang Xing, Hongyan Ying, Ji Li, Yang Gao, Zhao Sun, Jiarui Li, Chunmei Bai, Yuejuan Cheng, Huanwen Wu. Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive SystemFrontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00132
20
Ping Zhou, Yiyun Fu, Weiya Wang. Case Report: Gastrointestinal neuroendocrine carcinoma with SMARCA4 deficiency: a clinicopathological report of two rare casesFrontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1290717
21
Chunyan Hu, Shu Tian, Lan Lin, Jiahao Zhang, Hao Ding. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinomaOral Oncology 2020; 102: 104560 doi: 10.1016/j.oraloncology.2019.104560
22
Klaire Exarchou, Nathan A. Stephens, Andrew R. Moore, Nathan R. Howes, D. Mark Pritchard. New Developments in Gastric Neuroendocrine NeoplasmsCurrent Oncology Reports 2022; 24(1): 77 doi: 10.1007/s11912-021-01175-y
23
Krzysztof Kaliszewski, Maksymilian Ludwig, Maria Greniuk, Agnieszka Mikuła, Karol Zagórski, Jerzy Rudnicki. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)Cancers 2022; 14(8): 2028 doi: 10.3390/cancers14082028
24
Wei Liu, Lei Zhang, Zhiming Xiu, Jian Guo, Liye Wang, Yue Zhou, Yang Jiao, Meiyan Sun, Jianhui Cai. <p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>OncoTargets and Therapy 2020; : 7229 doi: 10.2147/OTT.S255491
25
Anja Rinke, Christoph J Auernhammer, Lisa Bodei, Mark Kidd, Sebastian Krug, Rita Lawlor, Ilaria Marinoni, Aurel Perren, Aldo Scarpa, Halfdan Sorbye, Marianne Ellen Pavel, Matthias M Weber, Irvin Modlin, Thomas M Gress. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?Gut 2021; 70(9): 1768 doi: 10.1136/gutjnl-2020-321300
26
Michele Prisciandaro, Maria Antista, Alessandra Raimondi, Francesca Corti, Federica Morano, Giovanni Centonze, Giovanna Sabella, Alessandro Mangogna, Giovanni Randon, Filippo Pagani, Natalie Prinzi, Monica Niger, Salvatore Corallo, Erica Castiglioni di Caronno, Marco Massafra, Maria Di Bartolomeo, Filippo de Braud, Massimo Milione, Sara Pusceddu. Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future PerspectiveFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.780716
27
Ioana Rada Popa Ilie, Carmen Emanuela Georgescu. Immunotherapy in Gastroenteropancreatic Neuroendocrine NeoplasiaNeuroendocrinology 2023; 113(2): 262 doi: 10.1159/000518106
28
Li Chen, Shaolong Huang, Qiang Liu, Xiangyi Kong, Zhaohui Su, Mengliu Zhu, Yi Fang, Lin Zhang, Xingrui Li, Jing Wang. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant ChemotherapyFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.849468